AlphaFold predicted structure
ZDHHC9 · Q9Y397

Mean pLDDT
84.3/ 100
Confident
364 residues
Confidence breakdown
- Very high(≥ 90)69%
- Confident(70–90)11%
- Low(50–70)7%
- Very low(< 50)13%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
zDHHC palmitoyltransferase 9
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
DDG2P
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesEarly onset or syndromic epilepsy
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesIntellectual disability
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesFetal anomalies
X-LINKED: hemizygous mutation in males, biallelic mutations in femalessyndromic X-linked intellectual disability Raymond type
X-linked intellectual disability with marfanoid habitus
hereditary disease
Intellectual disability
epilepsy
COVID-19
neurodegenerative disease
neurodevelopmental disorder
Neurodevelopmental abnormality
neoplasm
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Palmitoyltransferase ZDHHC9
Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates, such as ADRB2, GSDMD, HRAS, NRAS and CGAS (PubMed:16000296, PubMed:27481942, PubMed:37802025, PubMed:38530158, PubMed:38599239). The ZDHHC9-GOLGA7 complex is a palmitoyltransferase specific for HRAS and NRAS (PubMed:16000296). May have a palmitoyltransferase activity toward the beta-2 adrenergic receptor/ADRB2 and therefore regulate G protein-coupled receptor signaling (PubMed:27481942). Acts as a regulator of innate immunity by catalyzing palmitoylation of CGAS, thereby promoting CGAS homodimerization and cyclic GMP-AMP synthase activity (PubMed:37802025). Activates pyroptosis by catalyzing palmitoylation of gasdermin-D (GSDMD), thereby promoting membrane translocation and pore formation of GSDMD (PubMed:38530158, PubMed:38599239)
ZDHHC9 · Q9Y397

Mean pLDDT
84.3/ 100
Confident
364 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0